Entrectinib Brief Instructions for Use

Enrectinib, generic name: entrectinib, trade name: Luo Shengquan, English trade name: Rozlytrek, is an oral tyrosine kinase inhibitor developed by Genentech. The drug is mainly targeted at patients with solid tumors carrying NTRK fusion genes and adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The following is a brief introduction to entrectinib:

1. Specific application scope of indications:

Enrectinib is suitable for adult and pediatric solid tumor patients 1 months old and above who are diagnosed by confirmatory testing methods as carrying the NTRK fusion gene and who do not have known acquired resistance mutations. These solid tumors are metastatic or surgical resection may result in significant morbidity and progress after treatment or have no satisfactory alternative therapies.

Entrectinib is also indicated for adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

2. Medication guidance:

It is recommended to take it orally once a day, and the adult dose is 600mg. Pediatric patients need to determine the specific dose according to the body surface area.

Capsules should be swallowed whole and avoid opening or dissolving.

3. Precautions for use:

During the medication period, patients should pay close attention to their physical reactions and communicate with their doctor in time if they experience any discomfort or abnormal symptoms.

Avoid taking it with grapefruit or grapefruit juice to avoid affecting drug metabolism.

4. Potential side effects:

Entrectinib may cause a series of side effects, including fatigue, constipation, taste changes, edema, dizziness, etc.

Serious side effects may include congestive heart failure, central nervous system effects, fractures, and more.

5. Monitoring and program adjustment:

Doctors will regularly evaluate the patient's treatment effects and side effects and adjust the treatment plan as needed.

Patients should attend reexaminations on time to ensure the safety and effectiveness of treatment.

In conclusion, entrectinib, as a targeted therapy, provides a new treatment option for cancer patients carrying specific genetic mutations. However, before use, patients should fully understand the drug information and use the drug rationally under the guidance of a doctor. It is worth noting that entrectinib has been launched in my country and is included in medical insurance. Patients can consult the specific price and medical insurance policy. At the same time, affordable generic drugs are also available in Laos.